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ABSTRACT 
 
Introduction  
Non-small cell lung cancer and malignant pleural mesothelioma represent two of the 
most intriguing and scrutinized thoracic malignancies, presenting interesting 
perspective of experimental development and clinical applications.  
Areas covered 
In non-small cell lung cancer advanced-stage disease, molecular targeted therapy is 
the standard first-line treatment for patients with identified driver mutations; on the 
other hand, chemotherapy is the standard treatment for patients without EGFR 
mutations or ALK rearrangement or those with unknown mutation status. Once 
considered an ineffective therapy in pulmonary neoplasms, immunotherapy has been 
now established as one of the most promising therapeutic options. 
Mesenchymal stromal cells are able to migrate specifically towards solid neoplasms 
and their metastatic localizations when injected intravenously. This peculiar cancer 
tropism has opened up an emerging field to use them as vectors to deliver 
antineoplastic drugs for targeted therapies. 
Expert opinion 
Molecular targeted therapy and immunotherapy are the new alternatives to standard 
chemotherapy. 
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Mesenchymal stromal cells are a new promising tool in oncology and – although not 
yet utilized in the clinical practice, we think they will represent another main tool for 
cancer therapy and will probably play a leading role in the field of nanovectors and 
molecular medicine. 
 
KEYWORDS: non-small cell lung cancer; malignant pleural mesothelioma; 
immunotherapy; targeted therapy; mesenchymal stromal cell; drug loading and 
delivery. 
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INTRODUCTION 
 
Lung cancer is one of the most frequently diagnosed cancer and is the leading cause 
of cancer-related death worldwide.1 Non-small-cell lung cancer (NSCLC) - including 
squamous cell carcinoma, adenocarcinoma and large-cell carcinoma subtypes - 
accounts for approximately 85% of all new lung neoplasms while small-cell lung 
cancer (SCLC) represents the remaining 15%.2 
Overall primary pulmonary tumors represent 13% of the total newly diagnosed cancer 
cases and 19.4% of total cancer related deaths, worldwide every year.1 
Cigarettes smoking is the main risk factor for developing lung cancer: in fact, smoke 
exposure can lead to a well-described series of morphological modifications of the 
bronchial epithelium structure, evolving from basal cell hyperplasia to metaplasia, 
severe dysplasia to carcinoma in situ and, finally, frank carcinoma.3 
These pathologic modifications are mainly associated with the squamous subtype; on 
the contrary, although primary lung adenocarcinoma may develop in case of high 
carcinogen exposure and underlying pulmonary damage, it is commonly described as 
the more frequent histologic subtype in never-smoker patients with low carcinogen 
exposure;4 its progression is related to less well-characterized pre-neoplastic lesion 
called atypical adenomatous hyperplasia. SCLC also commonly occurs in case of high 
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carcinogen exposure, but it derives from pulmonary neuroendocrine cells and does 
not have well-characterized pre-malignant lesions.1 
From the therapeutic point of view, although NSCLC is a heterogeneous disease and 
its treatment should be personalized according to the patient’s characteristics, it is 
generally classified into three treatment categories: standard curative treatment for 
patients with resectable NSCLC is surgical resections; multimodal therapy 
(chemotherapy, surgery and radiotherapy) is indicated for locally advanced non 
metastatic patients; metastatic patients can be treated by standard chemotherapy, 
molecular targeted therapy or immunotherapy.5-7 
Malignant pleural mesothelioma (MPM) is an uncommon fatal asbestos-related 
tumor originating in the mesothelial cells of the pleurae. It can occur at any place 
where mesothelial cells de-differentiate from mesenchymal cells, including the 
pericardium, peritoneum, tunica vaginalis of the ovary and testis, although both 
pleurae (visceral and parietal pleura) are the most common affected structures.8, 9 
The incidence of MPM in in Japan and Europe are projected to peak in 2025 and 2020 
respectively, while the incidence in the USA has remained stable at 3000 deaths per 
year since peaking in 2004.10 
Surgical resection is the best therapeutic approach in early stages MPM (I, II and 
selected N0 stage III) without distant diffusion as well as radiotherapy as 
complementary or symptomatic treatment.11 A platinum-based doublet with a third-
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generation antifolate (pemetrexed (PMX) or raltitrexed) is the present front-line 
standard of care; on the contrary, there are no approved second-line treatments for 
MPM which remains a disease setting to test the efficacy of new therapeutic agents.8 
Both NSCLC and MPM – although different clinical and epidemiologic entities – 
nowadays represent two of the most intriguing and scrutinized thoracic malignancies, 
presenting interesting perspective of experimental development and daily clinical 
applications; the aim of the present review is to focus on preclinical and clinical 
aspects of medical therapy of NSCLC and MPM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BODY 
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In NSCLC advanced-stage disease, molecular targeted therapy is the standard first-
line treatment for patients with identified driver mutations; on the other hand, 
systemic cytotoxic chemotherapy is the standard treatment for patients without EGFR 
mutations or ALK rearrangement or those with unknown mutation status. 
 
NSCLC chemotherapy 
Standard first-line chemotherapy should be one of the platinum-based doublet 
chemotherapy regimens for patients with unknown mutational status or those 
without driver mutations.12, 13 
It has been demonstrated that pemetrexed-based combinations are superior to 
gemcitabine-based combinations for patients suffering from adenocarcinoma while 
efficacy is similar between the standard regimens (platinum plus any of paclitaxel, 
gemcitabine, docetaxel and vinorelbine).1 
When bevacizumab - that is a VEGF-specific monoclonal antibody – is added to 
standard chemotherapeutic regimen, it improves efficacy; on the contrary, it is 
contraindicated in patients affected by squamous cell carcinoma or presenting 
haemoptysis.14  
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In patients with non-squamous histology, if first-line treatment evokes a response or 
stabilizes disease, maintenance treatment with single-agent pemetrexed can be taken 
into consideration.15 
With the aim to research new drugs especially for intervention of drug-resistance lung 
cancer, different hybrid molecules between an oleanolic acid derivative (CDDO) and 
a diazeniumdiolate derivative (Figure 1, series I) was synthetized and in vitro 
evaluated on drug resistant A549/Taxol cells. One compound of the series revealed 
an anti-proliferative activity due to synergic effects of two drugs with enhanced 
generation of high levels of NO/ROS and increased the inhibition of stress response 
pathway through effect on Lon protease.16 A new series of 2-oxo-3,4-
diihydropyrimidinyl derivatives (Figure 1, series II) was synthetized and evaluated as 
suppressor of the proliferation of H520 NSCLC through irreversible binding with the 
FGFR1-3 target kinase and revealed a high potency also against FGFR4, resulting 
inhibitors of the FGFR family.17 Valid alternative anticancer alkaloids resulted the 
marine-derived molecules capable to interact with different targets. A series of 
analogues of renieramycin M (Figure 1, series III) possessed a nanomolar 
concentration cytotoxic activity against H292 and H490 human NSCLC cell lines. 
Investigation about the mechanism of action is in progress, allowing a future clinical 
application of the molecules considering the high activity demonstrated on lung 
cancer.18 
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Figure 1. Example of new compounds under evaluation for the treatment of NSCLC. 
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NSCLC new platinum drugs in vitro evaluation 
Platinum-based chemotherapy has been the standard first-line treatment for 
unselected patients with metastatic NSCLC, with median survivals of 8-12 months 
even if the therapeutic efficiency changes remarkably among patients. The main 
target of platinum drugs is DNA forming platinum-DNA adducts through intra- and 
interstrand crosslink. The resistance to these drugs largely depends on the enhanced 
DNA repair systems and the generic variations of DNA repair genes were important 
for the resistance and for the possibility to use their polymorphisms as platinum 
response genetic markers.19 The possibility to bypass the resistance in NSCLC patients 
is the base of the synthesis of new platinum(II) and platinum(IV) complexes, in vitro 
evaluated as promising anticancer agents. 
In the case of platinum(II) complexes, a novel class of homo- and heteroleptic 
complexes of ONN-donor hydrazone and 4-picoline (Figure 2, series IV) showed a 
potent cytotoxic effect comparable to cisplatin on lung cancer cell lines H460, 
suppressing cell growth effectively triggering apoptosis and inducing changes in 
morphology of cancer cells inhibiting also cell migration in lung cancer.20 A series of 
trans-platinum(II) oxadiazole complexes with 7-nitro-1,3,5-triaza-adamantane or 
hexamethylenetetramine ligands (Figure 2, series V) was evaluated in vitro as 
cytotoxic agents on lung cancer cell lines A549 revealing that six of mononuclear 
complexes of the series were more active in A546 than cisplatin at 2.5 μM 
concentration.21 A strategy for overcoming the drawbacks due to the use of 
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platinum(II) complexes consists in the oxidation of active square-planar platinum(II) 
species to an octahedral platinum(IV) complex that can act as prodrug through the 
activation by reduction process occurred in biological environment. Among a series 
of platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of 
microtubule polymerization, the complex VI (Figure 2) revealed to cause apoptotic 
cell death in human NSCLC cell line NCI-H460 both in vitro and xenograft mouse model 
in vivo through the mitochondrial mediated pathway and induced cell-cycle arrest at 
the G2/M phase.22 Another interesting series of platinum(IV) complexes, the 
cyclometallated iodido complex series VII (Figure 2), showed a cytotoxic activity 
against human lung cancer cell lines A-549 resulting topoisomerase I inhibitors. In 
particular two compounds of the series suppressed A-459 growth by apoptotic 
induction and call cycle arrest, and induced high levels of reactive oxygen species 
(ROS) involved in mitochondria permeabilization, consequently causing the realese of 
cytochrome c and finally the apoptosis.23 
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Figure 2. Some examples of novel platinum(II) and platinum(IV) complexes evaluated on NSCLC. 
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NSCLC molecular targeted therapy 
A wide variety of lung cancers with different characteristics exists, being the 
identification of driver oncogene mutations of paramount importance to understand 
these differences. These acquired genetic mutations in kinases result in constitutive 
signaling and, in susceptible cells, this leads to oncogenic transformation that is 
almost independent from other alterations. Oncogenes involved in NSCLC are 
activating mutations in the epidermal growth factor receptor (EGFR) gene and 
translocations of the anaplastic lymphoma kinase (ALK) gene. The EGFR and ALK 
driver mutations are mainly observed in occurred adenocarcinomas (10–60%), with a 
strong influence of smoking habits, being, in fact, more frequent in never smokers.24 
Several targeted therapies have been successfully applied for treating tumors 
harboring EGFR and ALK mutations, presenting satisfactory response rates; however, 
it is well known that neoplasms eventually acquire resistance to these targeted 
therapies, although the mechanisms by which resistance occurs are not yet fully 
understood. 
Less frequent mutations have also been described as targets, like translocations of 
RET, ROS1 and receptor tyrosine kinases, mutations in BRAF, MET, HER2 and 
amplifications of MET, HER2 and fibroblast growth factor receptor 1. Although 
mutations in the tumor suppressor genes TP53 and RB1 are commonly reported in all 
lung cancer histotypes, they are not yet therapeutically applicable. 
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In patients with advanced stage NSCLC, first-line EGFR TKIs are superior to standard 
platinum-based chemotherapy.25 The vast majority of patients would respond to 
EGFR TKIs but they will then almost always develop resistance, although the pattern 
of resistance is variable. In patients presenting systemic progressive disease with 
symptoms or fast progression, EGFR TKI therapy should be discontinued, and 
therapeutic protocol shifted to standard platinum-based chemotherapy. The most 
common cause of resistance is the T790M mutation, representing about 60% of all 
cases of EGFR TKI resistance.26 
Similar to mutations in EGFR, rearrangements in ALK are driver oncogenes, and 
patients with ALK-positive lung cancer are highly responsive to TKIs.27 
Crizotinib was the first TKI approved for first and subsequent lines of treatment of 
ALK-positive NSCLC, showing superior response rates and prolonged progression-free 
survival when compared to doublet chemotherapy; thus, all patients with 
adenocarcinoma should be tested for ALK rearrangement and first-line crizotinib 
should be offered to patients with ALK-positive lung cancer.  
ROS1 rearrangement is another driver oncogene that is highly responsive to 
crizotinib.28 An activating mutation in the ROS1 gene is observed in about 1% of lung 
adenocarcinomas, occurring most frequently in non-smoker young patients. The 
presence of these activating mutations is the therapeutic target for the low-
molecular-weight selective inhibitor of the ALK and ROS1 tyrosine kinase receptors – 
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crizotinib.29 
BRAF is a member of the serine/threonine kinase RAF family that is regulated by 
binding to RAS and directly activating MEK1/2, which can further phosphorylate 
ERK1/2. BRAF mutations are detected in approximately 2% to 4% of lung cancer, 
mainly adenocarcinomas. In vitro preclinical models of NSCLC demonstrated that both 
vemurafenib and trametinib were effective as single agents in BRAF V600E mutant 
cells; Sorafenib has also been reported to be active in patients with BRAF mutant 
NSCLC.30 
Despite an initial fast response to crizotinib, many patients develop resistance to this 
drug: one mechanism causing this resistance is a secondary mutation within the 
kinase domain of EML4-ALK, similar to that of T790M conferring resistance to EGFR-
TKIs in tumors with activating mutations of EGFR. Moreover, amplification of the ALK 
fusion gene and up-regulation of bypass signaling pathways mediated by EGFR, 
human epidermal growth factor receptor 2 (HER2), c-KIT, or the insulin-like growth 
factor-1 receptor have been found as mechanisms of crizotinib resistance.31 
Alectinib as well as ceritinib is highly selective second-generation ALK-TKIs developed 
for patients with NSCLC positive for ALK rearrangement; in particular Alectinib was 
found to possess potent antineoplastic activity against ALK fusion-positive NSCLC cells 
harboring the most common crizotinib resistance mutations.31 
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NSCLC immunotherapy 
Tumors develop genetic modifications to protect themselves from an effective human 
immune response. Immunotherapeutic strategies for the treatment of lung cancer 
involve a complex interaction between various components of the innate and 
adaptive immune systems. The involved cell types include CD8+ T lymphocytes 
(cytotoxicT-cells), Th1 and Th2 subtypes of CD4+ T lymphocytes (helper T-cells), NK, 
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Treg and macrophages. Each cell type plays a specific role in the immune cascade that 
ultimately leads to a cytotoxic response against the tumor cells.32  
The vast majority of solid cancers avoid host immune response and elimination by 
subversion of normal regulatory signals, like cytotoxic T lymphocyte-associated 
antigen 4 (CTLA4) - involved in T cell priming - and the programmed cell death protein 
1 (PD1) and PD1 ligand 1 (PDL1), involved in T cell killing.33 
Many NSCLCs, in fact, disclose upregulated expression of PDL1, which binds to PD1 
thus inactivating PD1-expressing T lymphocytes. A group of patients show effective 
and prolonged responses when treated with antibodies active on this pathway.34 
Once considered an ineffective therapy in pulmonary neoplasms, immunotherapy has 
been now established as one of the most promising therapeutic options: nivolumab, 
an anti–programmed death 1 (PD-1) antibody, and ipilimumab, an anti–cytotoxic T-
lymphocyte antigen 4 (CTLA-4) antibody, are immune checkpoint inhibitors with 
complementary mechanisms of action.35 
Patients with advanced NSCLC - without targetable mutations – can be treated using 
single agent immunotherapy as first-line therapy, depending on PD-L1 status. If the 
PD-L1 expression is ≥ 50%, then pembrolizumab can be considered for first-line 
therapy. Stage IV NSCLC patients who are intolerant to platinum-based chemotherapy 
or progress on or after platinum-based therapy, can be treated by pembrolizumab if 
PD-L1 tumor expression is ≥1%. Atezolizumab and Nivolumab have been approved for 
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second-line treatment for stage IV NSCLC irrespective of PD-L1 tumor expression and 
so they can be considered to treat patients without any detectable expression of PD-
L1. Durvalumab can be used as consolidation therapy for up to 12 months in patients 
with unresectable stage III NSCLC, presenting good response to chemoradiation.32  
 
 
 
 
 
 
 
 
MPM chemotherapy 
Currently approved first-line treatment for MPM is chemotherapy with pemetrexed 
plus cisplatin, which is associated with a median overall survival of approximately 12 
months.36, 37 
At present, there is no approved second-line treatments: therapeutic alternatives 
after ineffective response of first-line treatment are pemetrexed alone – in case of 
pemetrexed-naive in first line - platinum chemotherapy rechallenge (if patients had 
response in first line), vinorelbine or gemcitabine monotherapy, or participation in a 
clinical trial.38 Median overall survival with second-line therapy ranges from 5 to 10 
months,39 thus showing globally quite disappointing results. 
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Drug repositioning, using already approved drugs for new indications, is a promising 
strategy for identifying active molecules in a more rapid and less expensive way. In 
this regard, pyrvinium pamoate (PP) (Figure 3, compound VIII), a classical FDA-
approved anthelmintic, has recently attracted a great interest for its established 
inhibitory effect on the Wnt/β-catenin pathway known for playing a particularly 
important role in MPM progression.40 
The data showed that PP was able to decrease β-catenin levels in a time- and dose-
dependent manner as well as to reduce the expression of several key genes such as 
the VEGFA (vascular endothelial growth factor A) and MET (mesenchymal-epithelial 
transition) factor, whose expression are related to the invasiveness and 
aggressiveness of the MPM. Furthermore, it was found that PP acted synergistically 
with well-known approved chemotherapeutics such as doxorubicin, resulting 
practical and beneficial because of the already proven PP safety.  
Starting from a similar approach based on the reprofiling of known active molecules 
for new applications, a series of derivatives were synthesized from naftodipil, an α1- 
adrenoceptor blocker, clinically used and applied to the treatment of benign prostate 
hyperplasia but recently found to be able to induce apoptosis in MPM cells by 
activating caspase-8 and the effector caspase-3. 
Among the many derivatives that were synthesized and tested on different human 
MPM cell lines, HUHS1015 (Figure 3, compound IX) resulted the most active of the 
series in reducing cell viability with a greater potential than both cisplatin and 
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paclitaxel at concentrations higher than 30 µM. Its ability to induce apoptosis of MPM 
cells, probably through mitochondria, and to interfere with cell-cycle progression 
make HUHS1015 a promising candidate for the development of a new anticancer drug 
active on mesothelioma.41 
Another strategy employed in the effort to design new and more active 
chemotherapeutics for the treatment of MPM is based on the preparation of hybrid 
bifunctional agents with the aim to simultaneously inhibit multiple cellular targets 
involved in MPM growth and progression.  
Starting from the established ability to synergistically block cell proliferation between 
histone deacetylases inhibitors (HDAC) and camptothecin derivatives, a series of new 
compounds based on the psammaplin A scaffold, known for exerting a potent HDAC 
inhibitory activity, and camptothecin were synthesized showing a significant 
antitumor activity, with IC50 values in the nanomolar range on different 
mesothelioma cell lines (Figure 3, compounds X, XI and XII). Moreover, when tested 
in vivo on human a mesothelioma model, derivative XI showed a potent 
antiproliferative activity along with high tolerability, making it a particularly intriguing 
compound with encouraging future perspectives.42 
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Figure 3. Example of new compounds under evaluation for the treatment of MPM. 
 
 
 
MPM new platinum drugs in vitro evaluation 
Currently all chemotherapy protocols provide the use of cisplatin or carboplatin in a 
dual combinatorial association therapy with the antifolate pemetrexed (or 
raltitrexed) or with an immunotherapy agent (e.g. bevacizumab). If comorbidities are 
present carboplatin could be employed due to its milder toxicity profile if compared 
to cisplatin. Unfortunately, the efficacy of the current platinum-based therapy is really 
22 
 
modest due to a poor specificity and a higher chemoresistance to these alkylating 
agents that evoke the need for new compounds alternative to cisplatin to be found.11 
A first attempt made to overcome cisplatin resistance is based on the high glutathione 
(GSH) related metabolism that characterized MPM cells. Specifically, the enzyme 
GSH-S-transferase (GST) not only catalyzes the conjunction of cisplatin with GSH in a 
detoxification process but it results also involved in those protein-protein interactions 
with c-Jun N-terminal kinase, a member of the mitogen-activated kinases, whose 
activity is responsible for triggering cells apoptotic pathways. A dual compound able 
to combine the cytotoxicity of the metal core with the ability to target GST might 
represent a novel strategy to overcome MPM chemoresistance to platinum drugs. 
Dyson and co-workers43 developed in this context a Pt(IV) derivative containing a 
cisplatin equatorial base with two axial molecules of ethacrynic acid (EA), known for 
being a GST inhibitor. Upon reduction in the hypoxic tumor environment, the so called 
ethacraplatin (Figure 4, complex XIII) is supposed to release a cisplatin molecule and 
two equivalents of EA, that should be able to lower cisplatin resistance. As a term of 
comparison, the cis-diamminobis(ethacrynato)platinum(II) complex with the two EA 
moieties acting as leaving groups (Figure 4, complex XIII) was also synthesized and 
tested together with the Pt(IV) analogue on different primary MPM cancer cell lines.44 
Both complexes resulted more active than carboplatin with the platinum(IV) dual 
compound more potent in all cases with better resistance factors although less 
cytotoxic than cisplatin. In a similar manner the axial positions could be occupied by 
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different pharmacophores that in principle could offer the possibility to act on 
different targets in a synergistic way. A recent example provided the mono- and di-
insertion of clofibric acid (CA) moieties in axial position of a cisplatin-based 
platinum(IV) compound (Figure 4, complexes XIV and XV).45 The idea is to exploit the 
ability of CA, normally used for the treatment of dyslipidaemia, to activate the 
peroxisome proliferator-activated receptor α (PPARα), that besides controlling the 
fatty acid metabolism, is also reported to activate apoptosis and to degrade the 
hypoxia-inducible factor-1 α (HIF-1α) known for its implication in tumor growth and 
progression. Both complexes resulted able to bypass cisplatin resistance with the di-
clofibric acid derivative more effective on five different MPM cancer cell lines under 
the hypoxic conditions where cisplatin usually displays a weak cytotoxic activity.  
Another series of Pt(IV) compounds synthesized with the aim of bypassing the 
antioxidant inactivation exerted by thiol-containing molecules is based on picoplatin, 
used in a phase II trial as second line therapy for MPM patients with progressive 
disease only modestly responsive to the first-line treatment (Figure 4, complexes XVI, 
XVII and XVIII).46 In this case, the insertion of picoplatin in an octahedral Pt(IV) 
complex with carboxylic acids containing differently long carbon chains in axial 
positions should provide a prodrug easy to be reduced and more stable to GSH 
mediated detoxification activity, due to its monofunctional mechanism of action. On 
the tested MPM cancer cell lines, the activity of the picoplatin-based Pt(IV) series of 
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complexes showed a cytotoxic activity that increases along with the carbon chain 
length of the axial substituents. All the Pt(IV) complexes of the series resulted more 
potent than the parent picoplatin and a lower resistance factors than cisplatin.  
Among the novel strategies based on platinum compounds for the treatment of MPM 
malignancies, cationic platinum(II) complexes represent a class of compounds that, 
by violating the apparently demanded neutrality, could offer a distinct mechanism of 
action and a different antitumor profile thus allowing to furnish candidate drugs able 
to overcome cellular resistance and to lower toxicity of cisplatin in MPM patients. 
Once inside the cell, their cationic nature in fact might allow them to interact more 
rapidly with the anionic DNA. A series of imidazole based cationic Pt(II) complexes of 
general formula [Pt(N-N’)N’Cl]X- where N-N’ is an aminomethylimidazole ligand and 
the N’ an imidazole ring, both bearing the same alkyl group at the N1 position are very 
recently synthesized as shown in Figure 4 displaying interesting cytotoxic activity in 
many cisplatin resistant tumors with the one bearing a hexyl carbon chain at the N1 
(complex XXII) resulted more cytotoxic than cisplatin in NCI-H28 cancer cell line.47  
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Figure 4. Some examples of novel platinum(II) and platinum(IV) complexes evaluated for their 
cytotoxic activity on MPM. 
 
MPM immunotherapy 
Pembrolizumab is a high affinity, humanized monoclonal antibody against PD-1 
designed to block the interaction between PD-1 and both PD-L1 and PD-L2.48, 49 It is 
currently approved for advanced tumors, including advanced non-small-cell lung 
cancer (NSCLC) with a PD-L1 tumor proportion score of 50% or more, no EGFR or ALK 
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genomic aberrations, and no previous systemic therapy as well as advanced NSCLC 
with a PD-L1 tumor proportion score of 1% or more progressing on or after platinum 
containing chemotherapy.48, 49 
PD-L1 is expressed in up to 40% of patients suffering from malignant pleural 
mesothelioma and seems to be more common in non-epithelioid tumors.49 PD-L1-
positive malignant pleural mesothelioma appears to be associated with worse 
prognosis when compared to PD-L1-negative disease and is an independent risk 
factor for overall survival.50 
Initial results from non-randomized, open-label, phase 1 b trial show that 
pembrolizumab might be safe for the treatment of malignant pleural mesothelioma, 
with encouraging signs of anti-tumor activity in this population.51 
Nivolumab is a fully human monoclonal antibody that binds PD-1 on activated 
immune cells and disrupts binding of PD-1 to its ligand PD-L1. In recent a single arm 
phase II trial nivolumab has been shown to have meaningful clinical activity and an 
acceptable safety profile in second line unselected population of patients with 
mesothelioma. Further studies with a combination of checkpoint inhibitors - 
ipilimumab and nivolumab - are ongoing.51 
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MPM mesenchymal stromal cell experimental treatment  
Recent reports have shown that mesenchymal stromal cells (MSCs) are able to 
migrate specifically towards solid neoplasms and their metastatic localizations when 
injected intravenously. This peculiar cancer tropism has opened up an emerging field 
to use MSCs as vectors to deliver antineoplastic drugs for targeted therapies.8 
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Mesenchymal stromal cells (MSCs) are a group of undifferentiated multipotent adult 
cells residing within the human body; they are commonly described as plastic-
adherent, fibroblast-like cells disclosing clear self-renewal properties and the 
possibility to differentiate both in vivo and in vitro into a variety of mesenchymal 
lineage cells; they can differentiate into chondrogenic, osteogenic and adipogenic 
lineages when adequately cultured in selective media under specific inducing 
conditions.52, 53 
Once inserted in the host tissues, MSCs can interact with the surrounding 
microenvironment stimulating tissue healing, reparation and regeneration and 
exerting intense anti-inflammatory and immunomodulatory effects by several 
different mechanisms. At the beginning MSCs were thought to be only in bone 
marrow, but nowadays we know that MSCs can be isolated and characterized from 
many other adult and fetal tissues, including adipose tissue, dental pulp, umbilical 
cord, liver, tendon, thymus, cornea, brain, periosteum, spleen, placenta and synovial 
and amniotic fluids. Although no significant qualitative difference in the profiles of 
secreted cytokines by different type of MSCs has been reported, several quantitative 
differences in the cytokine secretions by adipose tissue-derived MSCs (AT-MSCs) and 
bone marrow-derived MSC (BM-MSC) have been observed. MSCs are able to migrate 
and engraft at sites of inflammation, tumors and injury in response to cytokines, 
chemokines and growth factors at a wound site; they can express local restoration 
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properties through trans-differentiation or mainly by the paracrine secretion of 
soluble factors with anti-inflammatory and wound-healing actions.54, 55 
The scope of chemotherapy is to maximize the drug effect in the neoplasm 
microenvironment to destroy as many cancer cells as possible with the lowest 
collateral damage. Nanovector of anticancer compounds have been recently 
developed, potentially improving the free-form drugs activity for several aspects: in 
fact, they can hide and protect the drug from being metabolized in the body before 
reaching their target site, thus enhancing tumor drug uptake and reducing drugs 
interaction with normal cells thereby decreasing clinical toxicity.56 Equivalent results 
can be reached by using MSCs for anti-tumor agent delivery, even considering that 
MSCs themselves generate antineoplastic factors able to kill cancer cells both in vitro 
and in vivo.  
We have previously demonstrated that paclitaxel-primed mesenchymal stromal cells 
and a cationic platinum(II) complex- primed mesenchymal stromal cells successfully 
inhibit the in vitro proliferation of human mesothelioma cells.8, 57 
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Other thoracic malignancies 
Although we focused our review on NSCLC and MPM, at least two other thoracic 
malignancies should also be mentioned to complete the clinical scenario of thoracic 
oncology: small cell lung cancer and thymic neoplasms. 
 
Small cell lung cancer 
Small cell lung cancer is a malignant primary pulmonary tumor belonging to 
neuroendocrine tumors, although presenting distinct clinical features, treatments 
and prognosis.  
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Limited disease has been historically treated by concomitant chemoradiotherapy with 
accelerated hyperfractionated radiation therapy concurrently with platinum-based 
chemotherapy; in case of extensive disease cisplatin is usually combined with either 
etoposide or irinotecan.58 
More recently, the safety and efficacy of pembrolizumab and nivolumab in advanced 
SCLC with at least 1% PD-L1 expression have been tested with results suggesting 
promising activity in patients with previously treated SCLC.59 
Rovalpituzumab – which is a delta like Notch canonical ligand 3 (DLL3)-targeted 
antibody drug conjugate - was developed in patients with recurrent SCLC, showing a 
promising result in patients with high DLL3 expression, representing 67% of the 
overall population.59 
Other agents like Tarextumab (a Notch-inhibitor), Veliparib (a poly(ADP-ribose) 
polymerase), Trilaciclib (a cyclin-dependent kinase 4 and cyclin-dependent kinase 6 
inhibitor) have been tested in SCLC patients but results are too preliminary to draw 
definitive conclusions.59 
 
Thymic neoplasms 
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Thymic neoplasms show a wide heterogeneity, being thymoma and thymic carcinoma 
the most frequent histological subtypes; the possibility to obtain complete resection 
is the most important aspect of the treatment and it is considered the gold standard.60  
Platinum-containing chemotherapy has been the standard treatment; more recently 
durvalumab has been tested as well as pembrolizumab in patients with refractory 
thymic epithelial tumors with an overall response rate of 24%.59 
EXPERT OPINION  
Molecular targeted therapy, immunotherapy and mesenchymal stromal cell drug 
loading and delivery are the new alternatives to standard chemotherapy; molecular 
targeted therapy – like EGFR TKIs – or immunotherapy – like pembrolizumab or 
nivolumab – are already a daily clinical reality while, on the contrary, MSC drug 
loading and delivery are at a preclinical phase. Anyway, both have shown excellent 
results that lead us to foresee a reduction of standard chemotherapy and an increase 
of less toxic and dangerous treatments. 
Pembrolizumab - a high affinity, humanized monoclonal antibody against PD-1 
designed to block the interaction between PD-1 and both PD-L1 and PD-L2 – and 
Nivolumab - a fully human monoclonal antibody that binds PD-1 on activated immune 
cells and disrupts binding of PD-1 to its ligand PD-L1 – represent some of the most 
innovative and promising compounds in the field of immunotherapy although EGFR 
TKIs still represent an excellent treatment option in responder patients. 
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Atezolizumab, a humanized anti-PD-L1 monoclonal immunoglobulin G1 antibody, is 
currently used in many kinds of advanced carcinoma including metastatic non-small 
cell lung cancer; moreover Durvalumab, a human IgG1 anti-PD-1 monoclonal 
antibody, has been approved for the treatment of patients with locally-advanced, 
unresectable NSCLC whose disease has not progressed following platinum-based 
chemoradiation therapy. 
In the short-term we expect a boost of immunotherapy compounds for NSCLC and 
MPM and probably many other neoplasms of different districts will be further treated 
with these regimens. 
With the development of immune checkpoint inhibitors, clinicians will have to rethink 
their evaluation of response to treatment by objective radiological findings: in fact, 
the so-called pseudoprogression has appeared as a relatively uncommon but 
concrete phenomenon, representing an objective tumor growth or appearance of 
new lesions, followed by tumor shrinkage. 
A deeper knowledge of the tumor microenvironment led to the emergence of 
immune checkpoint inhibitors that negatively regulate immune cells and bring to a 
dormant state, thus being immune cells unable to interact with their targets.  
Although immune checkpoint inhibitors are effective when used alone, several 
combined therapies exist. A better knowledge of the immune checkpoint biology and 
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of immune response against tumors, will lead to design many new compounds and 
therapeutic approaches in few years. 
Mesenchymal stromal cells are a new promising tool in the field of drug loading and 
delivery in oncology: they can migrate and engraft at sites of inflammation, tumors 
and injury in response to cytokines, chemokines, and growth factors at a wound site; 
they can express local restoration properties through trans-differentiation or mainly 
by the paracrine secretion of soluble factors with anti-inflammatory and wound-
healing actions.  
Although not yet utilized in the clinical practice, we think they will represent another 
main tool for cancer therapy and it will probably play a leading role in the field of 
nanovectors and molecular medicine. 
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CONCLUSION 
Non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM) 
represent the most intriguing and challenging diseases at the moment for thoracic 
oncologists and surgeons. On one hand, NSCLC is the leading cause of cancer-related 
death worldwide, but many new drugs and compounds have been recently developed 
with very interesting results; on the other hand, MPM - although rare – is a fatal 
asbestos-related tumor without any approved second-line treatments, thus 
representing a disease setting to test the efficacy of new therapeutic agents. 
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• Lung cancer is the leading cause of cancer-related death worldwide and 
malignant pleural mesothelioma – although rare – is fatal asbestos-related 
tumor without any approved second-line treatments. Together they are, for 
different reasons, the most challenging diseases for thoracic surgeons 
nowadays. 
• Although chemotherapy is still indicated in several non-small cell lung cancer, 
molecular targeted therapy and immunotherapy represent the new frontiers 
of daily clinical practice. 
• Activating mutations in the epidermal growth factor receptor (EGFR) gene and 
translocations of the anaplastic lymphoma kinase (ALK) gene are the most 
important mutations with concrete clinical implications, although many others 
are known. 
•  Immunotherapy has been now established as one of the most promising 
therapeutic options both in NSCL and MPM; immune-checkpoint inhibitors 
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have meaningful clinical activity and an acceptable safety profile both in NSCLC 
and MPM. 
• Nanovector of anticancer compounds as well as mesenchymal stromal cells can 
potentially hide and protect the drug from being metabolized in the body 
before reaching their target site, thus enhancing tumor drug uptake and 
reducing drugs interaction with normal cells thereby decreasing clinical toxicity. 
They can be considered the future of antineoplastic drug development. 
 
FIGURE LEGEND 
Figure 1: example of new compounds under evaluation for the treatment of NSCLC 
Figure 2: some examples of novel platinum(II) and platinum(IV) complexes evaluated 
on NSCLC 
Figure 3: example of new compounds under evaluation for the treatment of MPM 
Figure 4: some examples of novel platinum(II) and platinum(IV) complexes evaluated 
for their cytotoxic activity on MPM 
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